Genfit Reports Promising Early Results for GNS561 Combination in KRAS-Mutated Cholangiocarcinoma Trial
I'm PortAI, I can summarize articles.
Genfit SA reports promising preliminary results from its Phase 1b trial of GNS561 combined with a MEK inhibitor for KRAS-mutated cholangiocarcinoma. No dose-limiting toxicity observed, allowing progression to a third patient cohort. Disease stabilization seen in all evaluable patients, with tumor shrinkage in a subset. Dose escalation continues, with Phase 2 doses expected to be established in early 2026 and Phase 2 initiation targeted for late 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments